Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a biotechnology company focused on mRNA medicines, with multiple approved vaccines and a broad clinical pipeline. The MRNA news page on Stock Titan aggregates company announcements, investor updates and regulatory developments so readers can follow how Moderna’s strategy and pipeline progress translate into real-world events.
Investors and observers can use this feed to track commercial updates on products such as Spikevax, mRESVIA and mNEXSPIKE, along with developments in late-stage respiratory programs like the seasonal influenza vaccine mRNA-1010, the flu/COVID combination vaccine mRNA-1083 and the Norovirus vaccine candidate mRNA-1403. News items often cover regulatory submissions and opinions from agencies including the U.S. Food and Drug Administration, the European Medicines Agency, Health Canada and others.
The page also surfaces pipeline and clinical trial news in oncology and rare diseases, including updates on mRNA-4157 (intismeran autogene), mRNA-4359, mRNA-3927 for propionic acidemia and mRNA-3705 for methylmalonic acidemia. Announcements related to partnerships, such as CEPI’s funding commitment for the H5 pandemic influenza vaccine candidate mRNA-1018, appear here as well.
In addition, the MRNA news feed includes financial results, guidance and capital structure updates, such as quarterly earnings releases, multi-year financial frameworks and information on facilities like the $1.5 billion credit agreement. Corporate items, including participation in healthcare conferences, Analyst Day presentations and shareholder meeting outcomes, are also reflected.
By reviewing this consolidated news stream, readers can see how Moderna’s respiratory vaccine franchise, oncology and rare disease programs, manufacturing expansion and financing decisions evolve over time, all based on the company’s own disclosures and related announcements.
Moderna (Nasdaq: MRNA) has significantly expanded its workforce in Massachusetts, increasing from approximately 830 to 1,500 employees between March 2020 and March 2021. The company has created over 650 new jobs at its Norwood manufacturing facility. Moderna received a tax incentive from the Massachusetts Life Sciences Center for its commitment to employ 155 new full-time staff until 2025. A recent expansion in Norwood will boost Moderna's COVID-19 vaccine production capacity by 50%, aiming for up to 3 billion doses by 2022.
Moderna (Nasdaq: MRNA) has announced a U.S. government purchase of an additional 200 million doses of its COVID-19 vaccine, bringing the total confirmed commitment to 500 million doses. Deliveries include 110 million doses in Q4 2021 and 90 million in Q1 2022. As of June 14, 2021, Moderna has supplied 217 million doses. CEO Stéphane Bancel emphasized the collaboration's importance for vaccination efforts, including potential boosters. The company has received various authorizations globally for its vaccine and continues research funded by the U.S. government.
Moderna (Nasdaq: MRNA) has partnered with Magenta Investments to distribute the Moderna COVID-19 Vaccine and updated variant booster candidates in the UAE for 2021 and 2022. This agreement aims to enhance vaccine access in the region as part of a global effort against the COVID-19 pandemic. The Moderna vaccine utilizes an mRNA platform and has received various emergency authorizations across numerous countries. Moderna's commitment to innovation in vaccine technology continues to drive its position in the biopharmaceutical industry.
Rafael Holdings, Inc. (NYSE: RFL) announced the appointment of three new members to its Board of Directors: Ameet Mallik, CEO; Shannon Thyme Klinger, Chief Legal Officer of Moderna; and Mark McCamish, CEO of IconOVir Bio. Chairman Howard Jonas expressed optimism, stating the new board members bring significant expertise to advance the company's oncology pipeline. Ameet Mallik highlighted the importance of their industry experience in maximizing the potential of their therapeutics.
Moderna (Nasdaq: MRNA) announced the appointment of Paul Burton, M.D., Ph.D., as Chief Medical Officer, effective July 6, 2021. He brings over 16 years of experience from Johnson & Johnson, where he led global medical affairs. CEO Stéphane Bancel emphasized Burton's expertise as crucial for Moderna's international expansion and innovation in mRNA therapeutics. Burton’s background includes extensive publication in peer-reviewed journals and a focus on leveraging data science in medical engagement. His hiring follows the departure of previous CMO Tal Zaks after six years of service.
Moderna (Nasdaq: MRNA) has submitted an authorization application to Swissmedic for its COVID-19 vaccine's use in adolescents. CEO Stéphane Bancel expressed optimism about the vaccine's efficacy, noting a 100% effectiveness rate in a Phase 2/3 study with nearly 2,500 participants. The vaccine's safety profile remained consistent with previous studies, with mild adverse events reported. Moderna is also pursuing regulatory approvals globally, as it aims to aid in controlling the COVID-19 pandemic.
Moderna, Inc. (Nasdaq: MRNA) has entered into a partnership with Tabuk Pharmaceutical Manufacturing Company, a subsidiary of Astra Industrial Group, to commercialize the Moderna COVID-19 Vaccine and future variant-specific boosters in Saudi Arabia. Tabuk will hold marketing authorization, allowing for the distribution of Moderna's COVID-19 vaccine and potential mRNA products. This collaboration aims to enhance vaccine accessibility in Saudi Arabia and aligns with the country's Vision 2030. Moderna's CEO expressed gratitude for the partnership, emphasizing the importance of collaboration in global vaccine distribution.
Moderna (Nasdaq: MRNA) announced it has requested emergency use authorization (EUA) from the FDA for its COVID-19 vaccine in adolescents. The Phase 2/3 TeenCOVE study demonstrated 100% efficacy in nearly 2,500 vaccinated adolescents, with no COVID-19 cases observed. The vaccine was generally well tolerated, matching the safety profile seen in adult trials. Ongoing monitoring will assess long-term safety. Moderna has also filed for authorizations with Health Canada and the European Medicines Agency, emphasizing its commitment to ending the COVID-19 pandemic.
Moderna (Nasdaq: MRNA) has partnered with Medison Pharma to commercialize its COVID-19 Vaccine across Central Eastern Europe and Israel. This collaboration spans 20 markets, covering over 175 million lives. Medison Pharma's expertise in innovative therapies aligns with Moderna's mRNA technology to enhance vaccine accessibility. Both companies are committed to combating the pandemic through effective delivery and distribution. Despite this positive development, potential risks associated with mRNA technology and regulatory approval remain, as stated in Moderna's forward-looking statements.
Moderna, Inc. (Nasdaq: MRNA) has submitted its COVID-19 vaccine for authorization in adolescents to Health Canada. Following encouraging results from the Phase 2/3 TeenCOVE study, which showed 100% efficacy in nearly 2,500 adolescents, the company plans to seek further approvals from the European Medicines Agency and the U.S. FDA. The vaccine exhibited a well-tolerated safety profile, with no significant concerns identified. Moderna currently holds various emergency authorizations globally, demonstrating its commitment to combat the COVID-19 pandemic.